Equities research analysts expect Mallinckrodt PLC (NYSE:MNK) to announce sales of $828.63 million for the current quarter, Zacks reports. Seven analysts have provided estimates for Mallinckrodt’s earnings, with the lowest sales estimate coming in at $816.00 million and the highest estimate coming in at $841.60 million. Mallinckrodt reported sales of $631.70 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 31.2%. The firm is scheduled to announce its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that Mallinckrodt will report full year sales of $3.28 billion for the current fiscal year, with estimates ranging from $3.25 billion to $3.31 billion. For the next financial year, analysts anticipate that the business will report sales of $3.17 billion, with estimates ranging from $2.73 billion to $3.39 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Mallinckrodt.
Mallinckrodt (NYSE:MNK) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.73 by $0.21. Mallinckrodt had a positive return on equity of 14.22% and a negative net margin of 118.53%. The business had revenue of $791.00 million for the quarter, compared to analyst estimates of $766.27 million. During the same quarter in the prior year, the company earned $1.31 earnings per share. The company’s revenue was up 4.7% on a year-over-year basis.
A number of analysts have recently weighed in on MNK shares. ValuEngine raised Mallinckrodt from a “sell” rating to a “hold” rating in a research report on Monday, February 4th. Mizuho upped their price objective on Mallinckrodt to $26.00 and gave the stock a “neutral” rating in a research report on Thursday, February 28th. Morgan Stanley set a $32.00 price objective on Mallinckrodt and gave the stock a “hold” rating in a research report on Thursday, February 28th. Canaccord Genuity set a $40.00 price objective on Mallinckrodt and gave the stock a “buy” rating in a research report on Monday, March 18th. Finally, SunTrust Banks started coverage on Mallinckrodt in a research report on Tuesday, March 19th. They set a “hold” rating and a $23.00 price objective on the stock. Four equities research analysts have rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Mallinckrodt presently has a consensus rating of “Hold” and a consensus price target of $30.44.
Shares of Mallinckrodt stock traded down $1.65 during trading hours on Friday, reaching $13.03. 3,572,674 shares of the company were exchanged, compared to its average volume of 2,001,058. Mallinckrodt has a 1 year low of $12.95 and a 1 year high of $36.65. The company has a current ratio of 1.45, a quick ratio of 1.08 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $1.23 billion, a P/E ratio of 1.63, a P/E/G ratio of 0.15 and a beta of 2.12.
Large investors have recently bought and sold shares of the stock. CWM LLC increased its holdings in Mallinckrodt by 222.8% in the first quarter. CWM LLC now owns 1,159 shares of the company’s stock valued at $25,000 after buying an additional 800 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in Mallinckrodt by 1,480.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 520,326 shares of the company’s stock valued at $33,000 after buying an additional 487,394 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in Mallinckrodt by 210.4% in the fourth quarter. FNY Investment Advisers LLC now owns 2,288 shares of the company’s stock valued at $36,000 after buying an additional 1,551 shares during the last quarter. We Are One Seven LLC purchased a new position in Mallinckrodt in the fourth quarter valued at $38,000. Finally, QS Investors LLC increased its holdings in Mallinckrodt by 14.3% in the fourth quarter. QS Investors LLC now owns 4,000 shares of the company’s stock valued at $64,000 after buying an additional 500 shares during the last quarter.
Mallinckrodt Company Profile
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza.
See Also: Moving Average (MA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.